Nonviral DNA vectors for immunization and therapy: Design and methods for their obtention

Journal of Molecular Medicine

Volumn 82, Issue 8, 2004, Pages 500-509

  Rodríguez, Ernesto G ^a,b  

^a UNIVERSITY OF HAVANA   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

DNA immunization; Gene therapy; Linear closed DNA; Minicircle; Plasmid

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; DNA VACCINE; KANAMYCIN; LUCIFERASE; PLASMID VECTOR; TRANSFER RNA; VIRUS ANTIGEN; VIRUS VECTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIOPHAGE LAMBDA; BACTERIUM; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DNA REPLICATION; DNA SEQUENCE; DNA STRAND; DNA SYNTHESIS; DNA TRANSFER; DNA VECTOR; EPSTEIN BARR VIRUS; GENE CASSETTE; GENE DELETION; GENE SEQUENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION; INFLUENZA VIRUS; LACTOSE OPERON; MUTAGENESIS; NONVIRAL GENE THERAPY; PROMOTER REGION; REPORTER GENE; REVIEW; SIDE EFFECT;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; PLASMIDS; VACCINATION;

EID: 4344693878     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-004-0548-x     Document Type: Review

References (81)

1. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG (1993) Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 4:733-740
2. Alpar HO, Bramwell VW (2002) Current status of DNA vaccines and their route of administration. Crit Rev Ther Drug Carrier Syst 19:307-383
3. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA (1993) Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12:777-783
4. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, Robinson HL (1996) Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 70:3978-3991
5. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 7:1205-1217
6. Norman JA, Hobart P, Manthorpe M, Felgner P, Wheeler C (1997) Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine 15:801-803
7. Herrera AM, Rodriguez EG, Hernandez T, Sandez B, Duarte CA (2000) A family of compact plasmid vectors for DNA immunization in humans. Biochem Biophys Res Commun 279:548-551
8. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927-974
9. del Solar G, Giraldo R, Ruiz-Echevarria MJ, Espinosa M, Diaz-Orejas (1998) Replication and control of circular bacterial plasmids. Microbiol Mol Biol Rev 62:434-464
10. Azevedo V, Levitus G, Miyoshi A, Candido AL, Goes AM, Oliveira SC (1999) Main features of DNA-based immunization vectors. Braz J Med Biol Res 32:147-153
11. Ertl PF, Thomsen LL (2003) Technical issues in construction of nucleic acid vaccines. Methods 31:199-206
12. Prazeres DM, Monteiro GA, Ferreira GN, Diogo MM, Ribeiro SC, Cabrai JM (2001) Purification of plasmids for gene therapy and DNA vaccination. Biotechnol Annu Rev 7:1-30
13. Voss C, Schmidt T, Schleef M, Friehs K, Flaschel E (2003) Production of supercoiled multimeric plasmid DNA for biopharmaceutical application. J Biotechnol 105:205-213
14. Reyes-Sandoval A, Ertl HC (2004) CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther 9:249-261
15. Monteiro GA, Ferreira GN, Cabra, JM, Prazeres DM (1999) Analysis and use of endogenous nuclease activities in Escherichia coli lysates during the primary isolation of plasmids for gene therapy. Biotechnol Bioeng 66:189-194
16. Vieira J, Messing J (1982) The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. Gene 19:259-268
17. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M (1996) High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 7:1971-1980
18. Lin-Chao S, Chen WT, Wong TT (1992) High copy number of the pUC plasmid results from a Rom/Rop-suppressible point mutation in RNA II. Mol Microbiol 6:3385-3393
19. Bert AG, Burrows J, Osborne CS, Cockerill PN (2000) Generation of an improved luciferase reporter gene plasmid that employs a novel mechanism for high-copy replication. Plasmid 44:173-182
20. United States Food and Drug Administration (1996) Points to consider on plasmid DNA vaccines for preventive infectious disease indications. FDA, Washington
21. Blanca M, Mayorga C, Torres MJ, Warrington R, Romano A, Demoly P, Silviu-Dan F, Moya M, Fernandez J, Juarez C (2002) Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 32:192-197
22. Williams SG, Cranenburgh RM, Weiss AM, Wrighton CJ, Sherratt DJ, Hanak JA (1998) Represser titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26:2120-2124
23. Hanke T, McMichael AJ (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6:951-955
24. Soubrier F, Cameron B, Manse B, Somarriba S, Dubertret C, Jaslin G, Jung G, Caer CL, Dang D, Mouvault JM, Scherman D, Mayaux JF, Crouzet J (1999) pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther 6:1482-1488
25. Kornowski R, Fuchs S, Epstein SE, Branellec D, Schwartz B (2000) Catheter-based plasmid-mediated transfer of genes into ischemic myocardium using the pCOR plasmid. Coron Artery Dis 11:615-619
26. Donnelly J, Berry K, Ulmer JB (2003) Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 33:457-467
27. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039-3051
28. Lanford RE, Kanda P, Kennedy RC (1986) Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal. Cell 46:575-582
29. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J (1997) A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 4:1341-1349
30. Darquet AM, Rangara R, Kreiss P, Schwartz B, Naimi S, Delaere P, Crouzet J, Scherman D (1999) Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 6:209-218
31. Bigger BW, Tolmachov O, Collombet JM, Fragkos M, Palaszewski I, Coutelle C (2001) An araC-controlled bacterial ere expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem 276: 23018-23027
32. Chen ZY, He CY, Ehrhardt A, Kay MA (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8:495-500
33. Wils P, Escriou V, Warnery A, Lacroix F, Lagneaux D, Ollivier M, Crouzet J, Mayaux JF, Scherman D (1997) Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography. Gene Ther 4:323-330
34. Costioli MD, Fisch I, Garret-Flaudy F, Hilbrig F, Freitag R (2003) DNA purification by triple-helix affinity precipitation. Biotechnol Bioeng 81:535-545
35. Leutenegger CM, Boretti FS, Mislin CN, Flynn JN, Schroff M, Habel A, Junghans C, Koenig-Merediz SA, Sigrist B, Aubert A, Pedersen NC, Wittig B, Lutz H (2000) Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J Virol 74:10447-10457
36. Zanta MA, Belguise-Valladier P, Behr JP (1999) Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA 96:91-96
37. Schakowski F, Gorschluter M, Junghans C, Schroff M, Buttgereit P, Ziske C, Schottker B, Konig-Merediz SA, Sauerbruch T, Wittig B, Schmidt-Wolf IG (2001) A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3:793-800
38. Schirmbeck R, Konig-Merediz SA, Riedl P, Kwissa M, Sack F, Schroff M, Junghans C, Reimann J, Wittig B (2001) Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med 79:343-350
39. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, Sack F, Moreno S, Konig SA, Junghans C, Wittig B, Timon M, Esteban M (2002) DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21:247-257
40. Claas J, Wittig B (2003) Design principle for construction of expression constructs for gene therapy. International Patent Application WO 98/21322
41. Weiss R, Scheiblhofer S, Freund J, Ferreira F, Livey I, Thalhamer J (2002) Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20:3148-3154
42. Taki M, Kato Y, Miyagishi M, Takagi Y, Sano M, Taira K (2003) A direct and efficient synthesis method for dumbell-shaped linear DNA using PCR in vitro. Nucleic Acids Res Suppl 3:191-192
43. Sykes KF, Johnston SA (1999) Linear expression elements: a rapid, in vivo, method to screen for gene functions. Nat Biotechnol 17:355-359
44. Heinrich J, Schultz J, Bosse M, Ziegelin G, Lanka E, Moelling K (2002) Linear closed mini DNA generated by the prokaryotic cleaving-joining enzyme Te1N is functional in mammalian cells. J Mol Med 80:648-654
45. Deneke J, Ziegelin G, Lurz R, Lanka E (2000) The protelomerase of temperate Escherichia coli phage N15 has cleaving-joining activity. Proc Natl Acad Sci USA 97:7721-7726
46. Dean DA, Dean BS, Muller S, Smith LC (1999) Sequence requirements for plasmid nuclear import. Exp Cell Res 253:713-722
47. Mesika A, Grigoreva I, Zohar M, Reich Z (2001) A regulated, NFkappaB-assisted import of plasmid DNA into mammalian cell nuclei. Mol Ther 3:653-657
48. Langle-Rouault F. Patzel V, Benavente A, Taillez M, Silvestre N, Bompard A, Sczakiel G, Jacobs E, Rittner K (1998) Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids. J Virol 72:6181-6185
49. Chan CK, Hubner S, Hu W, Jans DA (1998) Mutual exclusivity of DNA binding and nuclear localization signal recognition by the yeast transcription factor GAL4: implications for nonviral DNA delivery. Gene Ther 5:1204-1212
50. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354
51. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
52. Bird AP (1987) CpG island as gene markers in the vertebrate nucleus. Trends Genet 3:342-347
53. Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA (2003) The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol 170:3614-3620
54. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM (2001) Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 167: 2602-2607
55. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM (1998) CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 160:4755-4761
56. Uwiera RR, Gerdts V, Pontarollo RA, Babiuk LA, Middleton DM, Griebel PJ (2001) Plasmid DNA induces increased lymphocyte trafficking: a specific role for CpG motifs. Cell Immunol 214:155-164
57. Stan AC, Casares S, Brumeanu TD, Klinman DM, Bona CA (2001) CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. Eur J Immunol 31:301-310
58. Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL (2002) DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 20:3263-3271
59. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng SH (2002) CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther 5:731-738
60. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL (1998) Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A 95:12631-12636
61. Rodriguez EG, Vazquez DM, Herrera AM, Duarte CA (2003) Enhanced cell-mediated EFN-γ-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering. Biochem Biophys Res Commun 308:713-718
62. Ross TM, Xu Y, Bright RA, Robinson HL (2000) C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1:127-131
63. Boyd AC, Popp F, Michaelis U, Davidson H, Davidson-Smith H, Doherty A, McLachlan G, Porteous DJ, Seeber S (1999) Insertion of natural intron 6a-6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination. J Gene Med 1:312-321
64. van Hall T, van de Rhee NE, Schoenberger SP, Vierboom MP, Verreck FA, Melief CJ, Offringa R (1998) Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res 58:3087-3093
65. Scheerlinck JY (2001) Genetic adjuvants for DNA vaccines. Vaccine 19:2647-2656
66. Templeton N (1999) Strategies for improving the frequency and assessment of homologous recombination. In: Methods in molecular biology, vol 133. Gene targeting protocols, Humana, Totowa
67. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92-100
68. MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB (2000) Safety and immune responses to a DNA-based human immunodeficiency virus (HFV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis 181:406
69. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL (2000) Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18:1893-1901
70. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R (1999) Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17:2826-2829
71. Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM (2002) Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 13:1595-1603
72. Safurdeen S, Karim A, Baxter C (2003) HIV vaccines and immunity. Curr Allergy Clin Immunol 16:67-69
73. Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Loffel J, Neubauer A, Albers P, Muller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG (2001) Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 12:267-278
74. Pouton CW, Seymour LW (2001) Key issues in non-viral gene delivery. Adv Drug Deliv Rev 46:187-203
75. Baker AH (2004) Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 84:279-299
76. Lundstrom K (2003) Latest development in viral vectors for gene therapy. Trends Biotechnol 21:117-122
77. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, Stout R, Jones TR, Richie TL, Parker SE, Doolan DL, Norman J, Hoffman SL (2001) Induction of CD4 (+) T cell-dependent CD8 (+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 98:10817-10822
78. Boyer JD, Cohen AD, Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB (2000) Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 181:476-483
79. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19:764-778
80. Robinson HL (2002) New hope for an AIDS vaccine. Nat Rev Immunol 2:239-250
81. McMichael A, Mwau M, Hanke T (2002) Design and tests of an HIV vaccine. Br Med Bull 62:87-98